High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival

Estrid V S Høgdall, Julia S Johansen, Susanne K Kjaer, Paul A Price, Lise Christensen, Jan Blaakær, Johannes E Bock, Eva Glud, Claus K Høgdall

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

YKL-40 (human cartilage glycoprotein-39) is a member of family 18 glycosyl hydrolases. YKL-40 is a growth factor and is secreted by cancer cells. High serum levels of YKL-40 in patients with colorectal cancer and recurrent metastatic breast cancer have been associated with a poor prognosis. We evaluated the prognostic value of plasma YKL-40 in patients with primary ovarian cancer (OC). YKL-40 was determined by ELISA in plasma obtained preoperatively from 47 women with stage III OC and in plasma from 79 healthy females. The results showed that plasma YKL-40 was elevated compared to healthy females in 57% of the OC patients and was highest in the patients who died during the follow-up compared to the patients still alive (186 vs. 78 micro g/l, p=0.002). Patients with high plasma YKL-40 (>130 micro g/l) had significantly (p=0.0003) shorter survival than patients with normal plasma YKL-40. Multivariate Cox regression analysis showed that plasma YKL-40 (RH=3.95; 95% CI, 1.52-10.27; p=0.005) and radicality after primary surgery (RH=4.03; 95% CI, 1.81-8.97; p=0.001) were independent prognostic factors of survival, whereas age, histological type of tumour and serum CA125 had no independent prognostic value. In conclusion, plasma levels of YKL-40 proved of prognostic value in stage III OC patients.
OriginalsprogEngelsk
TidsskriftOncology Reports
Vol/bind10
Udgave nummer5
Sider (fra-til)1535-8
Antal sider4
ISSN1021-335X
StatusUdgivet - 2003
Udgivet eksterntJa

Fingeraftryk

Ovarian Neoplasms
Hydrolases
Serum
Colorectal Neoplasms
Neoplasms
Regression Analysis

Citer dette

Høgdall, E. V. S., Johansen, J. S., Kjaer, S. K., Price, P. A., Christensen, L., Blaakær, J., ... Høgdall, C. K. (2003). High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncology Reports, 10(5), 1535-8.
Høgdall, Estrid V S ; Johansen, Julia S ; Kjaer, Susanne K ; Price, Paul A ; Christensen, Lise ; Blaakær, Jan ; Bock, Johannes E ; Glud, Eva ; Høgdall, Claus K. / High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. I: Oncology Reports. 2003 ; Bind 10, Nr. 5. s. 1535-8.
@article{61eb9b8474484ee6868ac69b4229e296,
title = "High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival",
abstract = "YKL-40 (human cartilage glycoprotein-39) is a member of family 18 glycosyl hydrolases. YKL-40 is a growth factor and is secreted by cancer cells. High serum levels of YKL-40 in patients with colorectal cancer and recurrent metastatic breast cancer have been associated with a poor prognosis. We evaluated the prognostic value of plasma YKL-40 in patients with primary ovarian cancer (OC). YKL-40 was determined by ELISA in plasma obtained preoperatively from 47 women with stage III OC and in plasma from 79 healthy females. The results showed that plasma YKL-40 was elevated compared to healthy females in 57{\%} of the OC patients and was highest in the patients who died during the follow-up compared to the patients still alive (186 vs. 78 micro g/l, p=0.002). Patients with high plasma YKL-40 (>130 micro g/l) had significantly (p=0.0003) shorter survival than patients with normal plasma YKL-40. Multivariate Cox regression analysis showed that plasma YKL-40 (RH=3.95; 95{\%} CI, 1.52-10.27; p=0.005) and radicality after primary surgery (RH=4.03; 95{\%} CI, 1.81-8.97; p=0.001) were independent prognostic factors of survival, whereas age, histological type of tumour and serum CA125 had no independent prognostic value. In conclusion, plasma levels of YKL-40 proved of prognostic value in stage III OC patients.",
author = "H{\o}gdall, {Estrid V S} and Johansen, {Julia S} and Kjaer, {Susanne K} and Price, {Paul A} and Lise Christensen and Jan Blaak{\ae}r and Bock, {Johannes E} and Eva Glud and H{\o}gdall, {Claus K}",
year = "2003",
language = "English",
volume = "10",
pages = "1535--8",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

Høgdall, EVS, Johansen, JS, Kjaer, SK, Price, PA, Christensen, L, Blaakær, J, Bock, JE, Glud, E & Høgdall, CK 2003, 'High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival', Oncology Reports, bind 10, nr. 5, s. 1535-8.

High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. / Høgdall, Estrid V S; Johansen, Julia S; Kjaer, Susanne K; Price, Paul A; Christensen, Lise; Blaakær, Jan; Bock, Johannes E; Glud, Eva; Høgdall, Claus K.

I: Oncology Reports, Bind 10, Nr. 5, 2003, s. 1535-8.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival

AU - Høgdall, Estrid V S

AU - Johansen, Julia S

AU - Kjaer, Susanne K

AU - Price, Paul A

AU - Christensen, Lise

AU - Blaakær, Jan

AU - Bock, Johannes E

AU - Glud, Eva

AU - Høgdall, Claus K

PY - 2003

Y1 - 2003

N2 - YKL-40 (human cartilage glycoprotein-39) is a member of family 18 glycosyl hydrolases. YKL-40 is a growth factor and is secreted by cancer cells. High serum levels of YKL-40 in patients with colorectal cancer and recurrent metastatic breast cancer have been associated with a poor prognosis. We evaluated the prognostic value of plasma YKL-40 in patients with primary ovarian cancer (OC). YKL-40 was determined by ELISA in plasma obtained preoperatively from 47 women with stage III OC and in plasma from 79 healthy females. The results showed that plasma YKL-40 was elevated compared to healthy females in 57% of the OC patients and was highest in the patients who died during the follow-up compared to the patients still alive (186 vs. 78 micro g/l, p=0.002). Patients with high plasma YKL-40 (>130 micro g/l) had significantly (p=0.0003) shorter survival than patients with normal plasma YKL-40. Multivariate Cox regression analysis showed that plasma YKL-40 (RH=3.95; 95% CI, 1.52-10.27; p=0.005) and radicality after primary surgery (RH=4.03; 95% CI, 1.81-8.97; p=0.001) were independent prognostic factors of survival, whereas age, histological type of tumour and serum CA125 had no independent prognostic value. In conclusion, plasma levels of YKL-40 proved of prognostic value in stage III OC patients.

AB - YKL-40 (human cartilage glycoprotein-39) is a member of family 18 glycosyl hydrolases. YKL-40 is a growth factor and is secreted by cancer cells. High serum levels of YKL-40 in patients with colorectal cancer and recurrent metastatic breast cancer have been associated with a poor prognosis. We evaluated the prognostic value of plasma YKL-40 in patients with primary ovarian cancer (OC). YKL-40 was determined by ELISA in plasma obtained preoperatively from 47 women with stage III OC and in plasma from 79 healthy females. The results showed that plasma YKL-40 was elevated compared to healthy females in 57% of the OC patients and was highest in the patients who died during the follow-up compared to the patients still alive (186 vs. 78 micro g/l, p=0.002). Patients with high plasma YKL-40 (>130 micro g/l) had significantly (p=0.0003) shorter survival than patients with normal plasma YKL-40. Multivariate Cox regression analysis showed that plasma YKL-40 (RH=3.95; 95% CI, 1.52-10.27; p=0.005) and radicality after primary surgery (RH=4.03; 95% CI, 1.81-8.97; p=0.001) were independent prognostic factors of survival, whereas age, histological type of tumour and serum CA125 had no independent prognostic value. In conclusion, plasma levels of YKL-40 proved of prognostic value in stage III OC patients.

M3 - Journal article

C2 - 12883737

VL - 10

SP - 1535

EP - 1538

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -

Høgdall EVS, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakær J et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncology Reports. 2003;10(5):1535-8.